期刊文献+

化疗与吉非替尼联合治疗50例晚期肺癌患者的临床观察

下载PDF
导出
摘要 目的对化疗和吉非替尼联合治疗晚期肺癌患者的临床效果观察。方法临床在我院2013年12月至2015年12月实施治疗的晚期肺癌患者中随机选取50例,依照患者的临床治疗方式将其分成两组,其中对照组患者给予培美曲塞、顺铂以及安慰剂治疗,观察组患者实施培美曲塞、顺铂与吉非替尼联合治疗,对比分析两组患者的临床效果及患者生存质量改善效果。结果和对照组患者相比,观察组患者的客观有效性显著偏高,差异显著P<0.05;和对照组患者相比,观察组患者的生活质量评分显著偏高,差异显著P<0.05;两组患者的临床不良反应发生率对比差异不大,对比P>0.05。结论在晚期肺癌患者临床治疗中,应用化疗及吉非替尼联合治疗,能够显著提高患者的生活质量及治疗有效性,值得推广应用。
作者 郭坤凡
出处 《中国医药指南》 2017年第2期128-129,共2页 Guide of China Medicine
  • 相关文献

参考文献8

二级参考文献47

  • 1张莉,于世英.吉非替尼单药治疗晚期非小细胞肺癌[J].中华肿瘤杂志,2006,28(7):539-541. 被引量:37
  • 2Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003, 21: 2237 -2246.
  • 3Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer:a randomized trial. JAMA, 2003, 290:2149-2158.
  • 4Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol, 2006, 1:847-855.
  • 5Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res, 2002, 62:2554-2560.
  • 6Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor(EGFR) downstream molecales as response predictive markers for gefitinib ( Iressa, ZD1839 ) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer, 2005, 113 : 109 - 115.
  • 7Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non- small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350: 2129-2139.
  • 8Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol, 2005, 23:2513-2520.
  • 9Chiu CH, Tsai CM, Chen YM, et al. Gefifinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer, 2005,47:129-138.
  • 10孙燕,石远凯.临床肿瘤内科杂志[M].第5版.北京:人民卫生出版社,2009:402.

共引文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部